Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR in Action: A Look at ACR Activities That Support Your Practice

Carina Stanton  |  February 1, 2018

As this practice becomes fully connected to the RISE registry, Dr. Kazi anticipates further improvements in patient care, closing gaps in care and engaging patients in their own care by having valuable dashboards to improve the delivery of effective care. “We will also be better positioned to assess and improve the MACRA-related reimbursement. The ACR has been instrumental in supporting practices by a combination of understanding the local microenvironment, and creating a nimble and agile product [the registry] to enable this transformation in care delivery,” Dr. Kazi says.

Dr. Huston agrees. “RISE has been extremely helpful in supporting and improving our reporting requirements in the MIPS program, and ACR outreach and educational programs have helped to better understand MACRA and predict its affect before the program started.” This support has helped Dr. Huston and his practice  be “prepared and engaged in efforts to achieve success in the era of MACRA and value-based payment.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

From the perspective of reducing administrative burdens, Matthew Behrens, compliance manager for Rheumatology Associates in Dallas, says participation with the RISE registry “has made submitting our data for MIPS easy, especially with the support we get from the ACR. This participation has allowed us to surpass our goal for the first year of MIPS implementation.”

RISE data also help the ACR develop quality measures that rheumatologists could choose to use for future value-based reimbursement in MACRA. ACR specialists, including Ryan Larosa, are available for individualized assistance navigating MACRA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The ACR is only a phone call or an email away from helping. Contact someone at the ACR or visit the website,” Dr. Huston suggests. He points to an enormous breadth and depth of information on the ACR website available to members.

One area of the website Dr. Edgerton suggests members become more familiar with is the committee structure, committee progress updates and committee members. He encourages members to email him or any member of CORC with concerns or questions. He also stresses the value of volunteering with the ACR. “It is through volunteering that one best understands the power of the ACR in supporting rheumatology practices.”

Dr. Worthing agrees. He would be thrilled to provide an update on current rheumatology-oriented legislation and regulation, and the practice and advocacy resources available from the ACR to academic, state and local rheumatology society meetings. Members can contact Dr. Worthing with requests for advocacy update presentations and questions.

Additional Resources
Read the ACR’s health policy statements and position statements to learn more about the official position the College takes on these and other critical elements of rheumatology practice.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:ACR advocacybiosimilar pricingdiagnostic MSUSpractice areaspractice supportreducing administrative burdensrheumatology-specific APMRISE registry

Related Articles

    Value-Based Care Continues to Evolve in Rheumatology

    April 24, 2023

    Value-based care in rheumatology continues to evolve, and rheumatologists can stay active with advocacy efforts behind value-based care and other government relations initiatives.

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences